| __timestamp | Axsome Therapeutics, Inc. | Geron Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 1392830 | 16758000 |
| Thursday, January 1, 2015 | 2419289 | 17793000 |
| Friday, January 1, 2016 | 6343648 | 18761000 |
| Sunday, January 1, 2017 | 7206691 | 19287000 |
| Monday, January 1, 2018 | 9351522 | 18707000 |
| Tuesday, January 1, 2019 | 13598030 | 20893000 |
| Wednesday, January 1, 2020 | 28896749 | 25678000 |
| Friday, January 1, 2021 | 66646205 | 29665000 |
| Saturday, January 1, 2022 | 159253661 | 43628000 |
| Sunday, January 1, 2023 | 323123000 | 69135000 |
| Monday, January 1, 2024 | 411359000 |
Infusing magic into the data realm
In the dynamic world of biotechnology, understanding financial trends is crucial for investors and stakeholders. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent biotech firms: Axsome Therapeutics, Inc. and Geron Corporation, from 2014 to 2023. Over this period, Axsome Therapeutics has seen a staggering increase in SG&A expenses, growing by over 23,000% from 2014 to 2023. In contrast, Geron Corporation's expenses have increased by approximately 312%, indicating a more conservative growth strategy. Notably, Axsome's expenses surged significantly post-2020, reflecting its aggressive expansion and investment in marketing and administrative capabilities. Meanwhile, Geron's steady rise suggests a focus on sustainable growth. These trends offer a window into each company's strategic priorities and market positioning, providing valuable insights for potential investors and industry analysts.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Axsome Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Takeda Pharmaceutical Company Limited and Geron Corporation
Operational Costs Compared: SG&A Analysis of Blueprint Medicines Corporation and Axsome Therapeutics, Inc.
Madrigal Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
Axsome Therapeutics, Inc. or Verona Pharma plc: Who Manages SG&A Costs Better?
Axsome Therapeutics, Inc. or Perrigo Company plc: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Axsome Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
Breaking Down SG&A Expenses: Axsome Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd.
Cost Management Insights: SG&A Expenses for Axsome Therapeutics, Inc. and Novavax, Inc.
Arrowhead Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
ImmunityBio, Inc. or Geron Corporation: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Agios Pharmaceuticals, Inc. vs Geron Corporation